United States Stomach Cancer Treatment Market Set for Breakthrough Growth with Innovative Therapies and Rising Global Demand 2025 | Top key players - Merck & Co, Bristol-Myers Squibb, Accord Healthcare.

Market Size and Growth:

The Global Stomach Cancer Treatment Market size reached US$ 4.7 billion in 2022 and is expected to reach US$ 10.3 billion by 2031 growing with a CAGR of 13.4% during the forecast period 2024-2031.

The Stomach Cancer Treatment Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Stomach Cancer Treatment market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/stomach-cancer-treatment-market?sz

The Stomach Cancer Treatment Market refers to the global industry focused on developing, manufacturing, and delivering therapies, drugs, surgical procedures, radiation, and supportive care solutions for gastric cancer management. It encompasses chemotherapy, immunotherapy, targeted therapy, minimally invasive surgery, and advanced diagnostics, driven by rising prevalence, technological innovations, and growing demand for effective and personalized treatment options.

Recent Key Developments of United States (U.S):

Immunotherapy for Early-Stage Disease: The Phase III MATTERHORN trial, presented at the ASCO 2025 Annual Meeting, showed that adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT) before and after surgery improved event-free survival in patients with resectable gastric or gastroesophageal junction (GEJ) cancer. This has the potential to become a new standard of care.

Advanced Immunotherapy Combinations: A clinical trial led by the National Institutes of Health (NIH), published in April 2025, demonstrated that a new form of tumor-infiltrating lymphocyte (TIL) therapy, when combined with pembrolizumab (Keytruda), showed a substantial reduction in tumor size in nearly a quarter of patients with metastatic gastrointestinal cancers, including stomach cancer.

Targeted Therapy for HER2-Positive Cancer: The Phase III DESTINY-Gastric04 trial presented at ASCO 2025 found that trastuzumab deruxtecan (Enhertu) extended survival by about three months for patients with advanced HER2-positive gastric cancer that had progressed after initial treatment. This positions the drug as a valuable second-line option.

FDA Approvals for Existing Drugs: The FDA granted a traditional approval to pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy for first-line treatment of HER2-positive, PD-L1-positive gastric or GEJ adenocarcinoma on March 19, 2025, converting its previous accelerated approval.

Focus on Diagnostics and Personalized Medicine: The market for gastric cancer diagnostics is growing, with a projected healthy CAGR of 7.09% from 2025 to 2034. There is an increasing emphasis on liquid biopsy, next-generation sequencing (NGS), and molecular profiling to guide personalized treatment plans, and advancements in AI-enabled digital pathology are improving early and more precise detection.

Key Players:

Merck & Co.
Bristol-Myers Squibb
Accord Healthcare
Sanofi S.A.
Bayer Pharma AG
Eli Lilly and Company
Teva Pharmaceuticals Industries, Ltd.
Celltrion, Inc.
Genentech, Inc.
Winthrop US.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=stomach-cancer-treatment-market

Market Segmentation:

By Cancer Type: Adenocarcinoma, Gastrointestinal stromal tumors (GIST), Carcinoid tumors, Lymphoma, Others.

By Treatment Type: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Others.

By Distribution Channel: Hospitals and Clinics, Cancer Care Centers, Cancer Research Institutes, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/stomach-cancer-treatment-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Stomach Cancer Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Stomach Cancer Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Stomach Cancer Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Stomach Cancer Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Stomach Cancer Treatment Market in 2025?
◆ What is the projected growth rate of the Stomach Cancer Treatment Market through 2033?
◆ Who are the key players in the Stomach Cancer Treatment Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.